E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Newly diagnosed paediatric patients with Acute Lymphoblastic Leukemia |
|
E.1.1.1 | Medical condition in easily understood language |
Acute Lymphoblastic Leukemia |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000845 |
E.1.2 | Term | Acute lymphoblastic leukemia |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the pharmacokinetics (PK) of both lyophilized and liquid S95014 formulations during the induction phase after a single intravenous (IV) dose in newly diagnosed paediatric patients with ALL |
|
E.2.2 | Secondary objectives of the trial |
To describe the PK of S95014 after administration of either lyophilized or liquid formulation
To evaluate the achievement of plasma asparaginase activity (PAA) of ≥0.1 U/mL after the administration of either lyophilized or liquid S95014
To assess the immunogenicity of both lyophilized and liquid S95014 formulations
To evaluate the safety profile through the occurrence of TEAEs including serious adverse events (SAEs), regardless of causality and severity |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients aged 1 to < 18 years
- Patients with cytologically confirmed and documented newly
diagnosed ALL according to National Comprehensive Cancer Network
guidelines2020 (see Appendix 2), excluding B-cell Burkitt ALL
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2(see Appendix 3)
- Highly effective contraception method
- Signed informed consent and assent, when appropriate |
|
E.4 | Principal exclusion criteria |
- Unlikely to cooperate in the study
- Pregnant and lactating women
- Participation in another interventional study at the same time; participation in non-interventional registries or epidemiological studies
is allowed
- Participant already enrolled in the study (informed consent signed)
- Women of childbearing potential tested positive in a serum pregnancy test within 7 days prior to the treatment period
- Inadequate hepatic function (bilirubin > 1.5 times upper limit of normal(ULN), transaminases > 5x ULN)
- Inadequate renal function defined as serum creatinine > 1.5 x ULN
- Prior treatment with chemotherapy or radiotherapy (except steroids andintrathecal therapy)
- Prior surgery or bone marrow transplant related to the studied disease
- Down Syndrome
- Psychiatric illness/social situation that would limit compliance with study requirements
- Known history of pancreatitis
- Known history of significant liver disease
- Known carriers of HIV antibodies
- Significant laboratory abnormality likely to jeopardize the patients' safety orto interfere with the conduct of the study, in the investigator's opinion
- Pre-existing known coagulopathy (e.g. haemophilia and known protein S deficiency)
- History of previous or concurrent malignancy
- History of sensitivity to polyethylene glycol (PEG) or PEG-based drugs
- Severe or uncontrolled active acute or chronic infection
- Uncontrolled intercurrent illness including life-threatening acute tumor lysissyndrome (e.g. with renal failure), symptomatic congestive heart failure,cardiac arrhythmia |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pharmacokinetics measurment :
- Area Under the Concentration-Time Curve (AUC)
- Maximum observed plasma asparaginase activity (Cmax) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 3 pre-dose just after the infusion,4h after the end of infusion; Day 4: 24h after the end of infusion;Day 5: 48h after the end of infusion; Day 8, Day 10, Day 12, Day 17, Day 21, Day 28 |
|
E.5.2 | Secondary end point(s) |
Pharmacokinetics measurements : additional PK parameters from the ones defined as primary endoint
Activity measurements : Plasma Asparaginase Activity (PAA) of ≥ 0.1 U/mL after the administration of either liquid or lyophilized S95014
Imunogenicity measurements : Anti S95014 and anti-PEG antibodies will be assessed for both lyophilized and liquid S95014 formulations
Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Advers Event (SAEs) causality and severity based on NCI CTCAE 5.0 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Pharmacokinetics measurements : 14 days post-dose
Activity measurements : Day 10, Day 17, Day 21 and Day 28 of induction
Imunogenicity measeurements: Day 3 pre-dose, Day 17 and Day 28
Incidence of TAEs and SAEs : Through study completion |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Pharmacokinetics comparability |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial is defined as the date of the last visit of the last participant. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |